Department of Biology, University of Padova, Padova, Italy.
Department of Experimental and Clinical Medicine, University of Firenze, Firenze, Italy.
Front Immunol. 2022 Jun 29;13:944139. doi: 10.3389/fimmu.2022.944139. eCollection 2022.
The miniferritin HP-NAP of was originally described as a neutrophil-activating protein because of the capacity to activate neutrophils to generate oxygen radicals and adhere to endothelia. Currently, the main feature for which HP-NAP is known is the ability to promote Th1 responses and revert the immune suppressive profile of macrophages. In this review, we discuss the immune modulating properties of the protein regarding the infection and the evidence that support the potential clinical application of HP-NAP in allergy and cancer immunotherapy.
最初, 被描述为一种嗜中性粒细胞激活蛋白,因为它具有激活嗜中性粒细胞生成氧自由基并黏附在内皮细胞上的能力。目前,HP-NAP 已知的主要特征是能够促进 Th1 反应并逆转巨噬细胞的免疫抑制特征。在这篇综述中,我们讨论了该蛋白在 感染方面的免疫调节特性,并提供了支持 HP-NAP 在过敏和癌症免疫治疗中潜在临床应用的证据。